Skip to main content
Premium Trial:

Request an Annual Quote

For Early-Stage Patients

The US Food and Drug Administration has narrowed the group of patients who could receive a controversial Alzheimer's disease drug, the Washington Post says.

The FDA approved aducanumab, Biogen's Aduhelm, in June, a decision that drew criticism and sparked resignations from an FDA advisory board. The board had voted in November against recommending approval and noted there was not enough data to gauge whether the drug was effective. While the FDA usually follows the recommendations of its advisory panels, the agency approved the drug under its accelerated approval pathway.

According to the Post, under the initial label, some 6 million people in the US with Alzheimer's disease may have been eligible for the treatment, which has a list price of $56,000 a year. NBC News previously reported that the drug could then cost the US government billions of dollars.

The new label now limits the drug to patients with early-stage disease, the Post says, noting that was the population in Biogen's trials. It estimates that the target patient population is now 1 million or 2 million.

According to CNN, Alfred Sandrock, the head of research and development at Biogen, says they submitted the new prescribing information in a bid to clarify the patient population studied in its trials.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.